RIG-I–Adjuvanted Immunogen Elicited T-Cell Immunity Controls Trypanosoma cruzi, Chagasic Cardiomyopathy, and Left Ventricular Dysfunction

Abstract

BCVR and BCV (bicistronic immunogen with and without RIG-I adjuvant) immunogens were designed in compliance with Food and Drug Administration guidelines. These immunogens were nontoxic, and highly effective in controlling the replication and persistence of Trypanosoma cruzi. Importantly, BCV/BCVR blocked the myocarditis, cardiac fibrosis, and left ventricular dysfunction that otherwise contribute to heart failure and sudden death in Chagas disease.